This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Trulieve Cannabis Corp
11/5/2026
Good morning, everyone, and welcome to the True Leave Cannabis Corporation Third Quarter 2026 Financial Results Conference Call. My name is Chuck, and I will be your conference operator today. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host for today's call, Ms. Christine Hersey, Chief Corporate Affairs and Strategy Officer for True Leave. Please go ahead.
Thank you. Good morning, and thank you for joining us. During today's call, Kim Rivers, Chief Executive Officer, and Jan Reese, Chief Financial Officer, will deliver prepared remarks on the financial performance and outlook for Trulieve. Following the prepared remarks, we will open the call to questions. This morning, we reported third quarter 2026 results. A copy of our earnings press release and PowerPoint presentation may be found on the investor relations section of our website, www.trueleave.com. An archived version of today's conference call will be available on our website later today. As a reminder, statements made during this call that are not historical facts constitute forward-looking statements, and these statements are subject to risks, uncertainties, and other factors that could cause our actual results to differ materially from our historical results or from our forecast, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, risk factors of the company's most recent annual report on Form 10-K, as well as our periodic quarterly filings. Although the company may voluntarily do so from time to time, it undertakes no commitment to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. During the call, management will also discuss certain financial measures that are not calculated in accordance with the United States Generally Accepted Accounting Principles, or GAAP. We generally refer to these as non-GAAP financial measures. These measures should not be considered in isolation or as a substitute for Trulieve's financial results prepared in accordance with GAAP. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is available in our earnings press release that is an exhibit to our current report on Form 8K that we furnished to the SEC today and can be found in the investor relations section of our website. Lastly, at times during our prepared remarks or responses to your questions, we may offer metrics to provide greater insight into the dynamics of our business or our financial results. Please be advised that we may or may not continue to provide these additional details in the future. I'll now turn the call over to our CEO, Kim Rivers. Thank you, Christine.
Good morning, everyone, and thank you for joining us today. We are thrilled to report third quarter results that exceeded guidance with higher revenue, margins, and cash generation. Third quarter results represent medical-only markets in our first full quarter listed on the New York Stock Exchange. This is an incredibly exciting time for our company. For anyone new to Trulieve, we are the largest US medical cannabis operator with 208 dispensaries and 3.5 million square feet of production capacity. We are in the early stages of an accelerated growth period fueled by organic market development, acquisition opportunities, regulatory catalysts, and continued adoption of cannabis. Before we discuss our quarterly results, I'd like to share some perspective on rescheduling and how Trulieve is positioned. Thank you for joining us. First, he issued a final order to reschedule state-licensed medical marijuana to Schedule 3. And second, he restarted the rulemaking process to reschedule marijuana more broadly to Schedule 3. The first action, rescheduling a state-licensed medical marijuana, triggered three major positive developments for Trulieve. One, registration with the DEA. Two, removal of the 280E punitive tax burden. And three, uplisting to the NYSE. I'll touch briefly on each area. First, Trulieve registered all of its medical-only marijuana dispensaries and production facilities with the DEA, complying with the final order. Since then, the DEA has completed inspections and began issuing final registrations at all of our medical dispensaries and production sites. With DEA registration and state licensure, Trulieve is a federally legal Schedule III operator. This is an important differentiator for us as it opens the door for new strategic partnerships and service providers. Second, concurrent with rescheduling of state-licensed medical marijuana, the Treasury Department issued a press release confirming that punitive 280e tax does not apply to state-licensed medical operators under Schedule 3. From this year forward, we are taxed the same as any U.S. corporation. This parity is important because it improves profitability and cash flow while acknowledging the medical status of our business. Third, state-licensed medical marijuana rescheduling enabled Trulieve to list on the NYSE. As the largest U.S. medical operator, Trulie was uniquely positioned to segregate its business into two parts, separating the non-medical mixed-use market from our medical-only business. Trulie listed its medical-only Schedule III business on the NYSE in June. Since uplisting, we have realized higher daily trading volume, reduced swap exposure, expanded access to institutional investors, and inclusion in several indices such as the S&P Total Market Index and the Morningstar Total Stock Market Index. We expect Trulieve will be added to additional indices in the coming year. Altogether, Trulieve has realized meaningful benefits from rescheduling of state-licensed medical marijuana. Turning now to our third quarter results. As a reminder, results include markets serving only medical patients. During the third quarter, the team outperformed in multiple ways, delivering impressive execution in our core markets while rapidly expanding in Georgia and preparing to build out vertical operations in Texas. Third quarter revenue of $230 million grew 4% year over year and sequentially compared to medical-only revenue in prior periods. Medical revenue exceeded guidance and outperformed typical seasonal trends. Compared to medical-only results last year, third quarter gross margin of 64% improved 1%, reflecting operational efficiencies, low production costs, and our disciplined approach to promotional activity. Adjusted EBITDA of $89 million, or 39% margin, was driven by expense control in our core business. During the quarter, we generated $74 million in operating cash flow, which contributed to our quarter end cash balance of $327 million. Subsequent to quarter end, we fully repaid a $65 million mortgage secured by our cultivation campus in Jefferson County, Florida. The reduction in debt lowers annual interest expense, improving profitability and cash flow. Retail revenue grew 2% sequentially due to growth in Georgia and Pennsylvania. Traffic increased 3%, partially offset by a slight sequential decline in average basket size. Units sold were up 2%. In Georgia, traffic and units increased sevenfold with market expansion and new product types including concentrates, flour, and vapes. In Pennsylvania, higher traffic and strength in the wholesale channel contributed to revenue growth. Results in Florida were consistent with typical seasonal trends. Trulia sold 55% more flour per store than the state average across 170 stores, totaling 657,000 ounces. We sold 1.4 billion milligrams of oil, more than two times the next highest competitor. Across our branded retail platform, customer trends have been consistent throughout the year, with some mid-tier customers leaning into value products, while the premium segment remains unchanged, with a focus on exclusive top shelf products. Our investment in Harvest performed well in the third quarter, with revenue growth and margin expansion compared to the second quarter, driven largely by growth in Ohio. As we approach year end and the busy holiday season, our team is carrying the momentum forward. At the start of the year, we identified four strategic initiatives to focus on. One, expanding access to cannabis. Two, investing in growth initiatives. Three, elevating our branded product portfolio. And four, growing our loyal customer base. Year to date, we have made significant progress in all four areas. First, I'd like to discuss expanding access to cannabis, which is central to our mission here at Trulieve. 2026 has been a pivotal year with historical federal policy changes and expansion in state markets such as Georgia. Federal rescheduling of state licensed medical marijuana removes barriers for research, reduces stigma for patients and physicians, and provides a level playing field for lawful operators, enabling additional investments in patient access. We remain optimistic that broader rescheduling will happen in the near term. We expect the Treasury Department will issue additional guidance on tax treatment, including potential retroactive relief, following completion of the rescheduling process. Following the midterm elections, cannabis reform remains a central theme across the country. We look forward to continuing to work with Congress to advance cannabis policy into 2027. Alongside rescheduling, we remain supportive of additional reform, including updated FinCEN guidance and safe banking. These measures reduce friction for operators, support credit card payments and dispensaries, and ease restrictions on banking and service providers. Our second strategic growth priority is investing in growth initiatives, which includes both organic and acquisition opportunities. We believe Georgia and Texas present meaningful organic growth opportunities for Trulieve. In Georgia, following changes to the state medical marijuana program and federal rescheduling for state licensed operators, we are pursuing two pathways for growth. The first is expansion of our licensed medical dispensary network. Today, we own and operate seven dispensaries that serve qualified patients with our branded products. Yesterday, we received approval to open our eighth and ninth dispensaries, which we anticipate will open in the coming months. The state program is designed to provide expanded access as the patient count grows. With 80% patient growth since the start of the year, the patient count recently surpassed 60,000. We can request an additional location for every 10,000 patients that enroll. We plan to apply for our 10th dispensary this month once the patient count reaches 65,000 patients. The second growth area is wholesale distribution of branded products to independent pharmacies. In Georgia, independent pharmacies can register with the state and the DEA to dispense approved medical marijuana products to registered patients. Today, we are shipping to almost 20 pharmacies. While development of this channel remains ongoing, early progress is encouraging. Over 30 more pharmacies are ready to commence sales of Trulieve products pending licensure, and over 125 independent pharmacies previously expressed interest. Our team is meeting with pharmacy owners across Georgia to discuss medical cannabis and share information on how to apply for state NDEA licenses. In support of growth in Georgia, we have been increasing production capacity since last spring. Our Georgia operations are fully vertically integrated, where we produce all of the cannabis products that we sell in our dispensaries. As I mentioned, third quarter units sold increased by seven times the amount sold in the second quarter. Newly launched in-house brands Modern Flower and Roll One accounted for 70% of our branded units sold in Georgia. Our team has done a fantastic job managing through the period of rapid growth. Today, we have adequate supply to service our current business, and we are adding capacity in stages into 2027 to meet growing demand in all channels. While the Georgia market is rapidly expanding now, we believe Texas represents the largest medical cannabis opportunity in the US. Last December, Trulie was awarded a conditional license. We are working through the process to convert the conditional award to a final license. We expect the next steps include completion of financial review and site inspections. Our initial production capacity is ready for inspection, and we have a robust retail pipeline of stores covering all regions. Pending final licensure, our team is ready to quickly ramp to serve Texas patients. New patients can enroll in the program through convenient telehealth consultations. Easy program entry, greater product variety, and increased awareness all support rapid program growth. We plan to replicate the success we've had in other markets, like Florida and Georgia, by scaling modularly as the patient count increases over time. Alongside investments in Georgia and Texas, we are actively evaluating acquisition opportunities ranging from tuck-in assets to larger single and multi-state operations. We expect consolidation in the cannabis industry will continue for the foreseeable future. Our stringent evaluation criteria includes price, strategic fit, quality of assets, and market framework. The strength of our core business and cash flow generation allow us the flexibility to consider acquisition opportunities while remaining disciplined to ensure transactions enhance long-term shareholder value. While reform and growth initiatives continue to advance, we remain committed to operational excellence in our core business. This brings us to our third initiative, which is elevating our branded product portfolio. Serving our customers consistently with high-quality branded products is a key ingredient to our success. Our branded product portfolio includes both in-house brands and partner brands. In the third quarter, we sold over 10 million branded product units in our medical dispensaries, with in-house brands Modern Flower and Roll One accounting for 55% of the units sold. We complement in-house brands with partner brands to add variety for our customers. In September, we closed on a master licensing agreement with Connected. This agreement affords us exclusive, perpetual, royalty-free rights to genetics, trademarks, and know-how for Alien Labs and Connected branded products in Florida and Texas and has a payback period of less than two years. Since 2022, Trulieve has been the exclusive provider of Alien Labs and Connected Premium Flower in Florida. We plan to introduce new Alien Labs and Connected categories and form factors in Florida, including vapes and concentrates, as soon as the first half of 2027. The agreement provides Trulieve with the right of first refusal for exclusive licensing rights and additional expansion markets. Availability of top shelf premium products supported with collaborative marketing campaigns reinforces customer acquisition and retention. We will continue to enhance our assortment with new and innovative branded products. Turning now to our fourth initiative this year, growing our loyal customer base. Since inception, Trulieve has embraced a customer-centric approach to building our company, reinforcing acquisition and retention. We use a combination of digital outreach, paid media, and in-person events to attract new customers to Trulieve. Across our platform, we conduct over 100 community and physician engagement events per month. Partnering with a wide variety of nonprofit organizations to raise awareness for cannabis. Establishing and maintaining reciprocal relationships with our customers is essential for customer retention. Customer retention remains strong at 75%, highlighting the success of our approach. Consistent customer retention requires availability of high-quality products, timely and informative messaging, and exceptional service. Over the past three years, we've invested significantly in talent, technology, and training to reinforce our customer messaging and service. As our marketing capabilities evolve, we are adding more sophisticated functionality. Together, personalized messaging rewards program and mobile app provides customers with convenient real-time updates. Earlier this year, we launched an initiative called Project Hyper that uses generative AI to enable personalized customer messaging at scale. This initiative is on track and we expect to begin realizing efficiency and speed to market benefits in the first quarter of 2027. Our rewards program added over 45,000 members in the third quarter, surpassing 700,000 members. Rewards members spend on average 2.1 times more than non-members, comprising more than 80% of third quarter transactions. In May, we added tiers to the rewards program in Florida, giving our most loyal customers greater rewards. Following the early success in Florida, we are rolling out tiered rewards in Georgia this month. One year ago, we launched our Florida mobile app, giving patients a more convenient way to browse products, access deals and rewards, and place orders. Adoption continues to exceed expectations with more than half a million orders, or 30% of all online orders, placed through the app in the third quarter. We plan to launch the mobile app in Georgia soon, followed by additional markets in 2027. In summary, we have made substantive progress on our strategic priorities with notable wins across reform, growth initiatives, branded products, and customers. As we approach year end, our team is laser focused on maintaining operational excellence in our core business while prepping for the next wave of accelerated growth. With that, I'd like to turn the call over to our CFO, Jan Reese. Please go ahead.
You're reading a preview of the TCNNF Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing